Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection

Title:Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection

Volume: 5

Author(s): Alberto Boretti*Bimal Banik

Affiliation:

• Independent Scientist, Wellington, New Zealand

Keywords: Hydroxychloroquine, COVID-19, early treatment, outpatient, meta-analysis, efficacy, critique, objective assessment, treatment delay, pre-existing conditions.

Abstract: A recent study has claimed that nearly 17,000 people in the U.S. and five other countries died prematurely during the early stages of the COVID-19 pandemic due to the compassionate use of hydroxychloroquine (HCQ) for treatment. However, this study's conclusions are contentious due to reliance on flawed data and the neglect of significant evidence supporting HCQ's efficacy in early outpatient treatment. Our critique challenges the validity of the study, highlighting its methodological weaknesses and the confounding factors it overlooked. By reviewing the comprehensive body of scientific literature, we demonstrate that treatment with HCQ, particularly in combination with zinc and antibiotics, consistently yielded positive outcomes, especially in the early stages. This work aims to provide a balanced and objective assessment of HCQ's impact on COVID-19, emphasizing the importance of early intervention and proper dosage.

Cite this article as:

Boretti Alberto*, Banik Bimal, Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses 2024; 5 () : e26667975327612 . https://dx.doi.org/10.2174/0126667975327612240902104505